Wednesday, November 29, 2023 4:24:40 PM
CaptainObvious,
I’ll admit that this is a concern when you are kept in the dark but two things, maybe 3, stand out strongly against this and they are her share count in a company with massive platform technology upside, fiduciary duty and legacy as a patient advocate.
As stated by others Linda gains biggest by NWBO share price. The sheer number of shares she has or has control over dictate that millions (CDMOs) vs billions (NWBO) of dollars is the likely comparison which makes it really no comparison.
Her fiduciary duty gets her and the board in deep (jail time) trouble if she creates a structure that unfairly creates an unjustifiable advantage for herself or other insiders over other investors. Those who want her to fail would have attempted from this angle already if there was anything to prove. They can claim stuff all they want but they are not willing to back their claims so what does that tell you? No leg to stand in?; ).
Linda Powers is building a legacy based on being a supremely focused, goal oriented, personal experience driven, patient focused, tech entrepreneur investor advocate who hired one of many surviving DCVax patients and the daughter of another as an NWBO reps. She did this before DCVax-L hits the big time so that they will be there as proof of what NWBO has always been about. Unlike many of the fudsters on this board, Linda Powers actually has a reputation to uphold of being a goal oriented winner in spite of heavy opposition, even by them ; ). Best wishes.
I’ll admit that this is a concern when you are kept in the dark but two things, maybe 3, stand out strongly against this and they are her share count in a company with massive platform technology upside, fiduciary duty and legacy as a patient advocate.
As stated by others Linda gains biggest by NWBO share price. The sheer number of shares she has or has control over dictate that millions (CDMOs) vs billions (NWBO) of dollars is the likely comparison which makes it really no comparison.
Her fiduciary duty gets her and the board in deep (jail time) trouble if she creates a structure that unfairly creates an unjustifiable advantage for herself or other insiders over other investors. Those who want her to fail would have attempted from this angle already if there was anything to prove. They can claim stuff all they want but they are not willing to back their claims so what does that tell you? No leg to stand in?; ).
Linda Powers is building a legacy based on being a supremely focused, goal oriented, personal experience driven, patient focused, tech entrepreneur investor advocate who hired one of many surviving DCVax patients and the daughter of another as an NWBO reps. She did this before DCVax-L hits the big time so that they will be there as proof of what NWBO has always been about. Unlike many of the fudsters on this board, Linda Powers actually has a reputation to uphold of being a goal oriented winner in spite of heavy opposition, even by them ; ). Best wishes.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
